OP0284 Long Noncoding RNA MIR503HG is a Novel Factor in the Pathogenesis of Systemic Sclerosis

BackgroundLong noncoding RNAs (LncRNAs) are a novel class of noncoding transcripts with diverse regulatory functions, e.g. imprinting regulation, dosage compensation, cell cycle regulation, pluripotency and retrotransposon silencing. Dysregulation of lncRNAs is increasingly recognized to contribute...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.180-180
Hauptverfasser: Pachera, E., Assassi, S., Salazar Cintora, G., Frank-Bertoncelj, M., Haunerdinger, V., Dobrota, R., Brock, M., Vettori, S., Hellerbrand, C., Feghali-Bostwick, C., Distler, J., Kania, G., Distler, O.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundLong noncoding RNAs (LncRNAs) are a novel class of noncoding transcripts with diverse regulatory functions, e.g. imprinting regulation, dosage compensation, cell cycle regulation, pluripotency and retrotransposon silencing. Dysregulation of lncRNAs is increasingly recognized to contribute to the disease pathogenesis, such as cancer, autoimmune disorders and neurodegeneration.ObjectivesTo identify candidate lncRNAs in systemic sclerosis (SSc) and investigate their function, in particular in relation to the TGFβ pathway and myofibroblast phenotype development.MethodsRNA Sequencing Ilumina HiSeq2000 was performed in healthy and SSc skin biopsies. Human skin fibroblasts were isolated from biopsies of SSc patients and healthy controls (HC), human pulmonary smooth muscle cells were purchased from Lonza. The cells were treated with 10 ng/ml TGFβ. TGFβR1 inhibitors (SD208 and SB431542) and siRNA against SMAD3 were used to investigate TGFβ driven gene expression. The lncRNA MIR503HG was silenced in skin fibroblasts using locked nucleic acid antisense oligonucleotides (LNA GapmeRs), followed by qPCR analyses and immunofluorescence staining. The expression of MIR503HG was measured in tissue samples of liver and lung fibrosis.ResultsRNA sequencing showed a significant upregulation of the lncRNA MIR503HG (H19X) in SSc versus HC skin biopsies. Importantly, the upregulation of MIR503HG was not limited to SSc skin, but present also in the tissues from liver and lung fibrosis, indicating a broader role of MIR503HG in fibrotic diseases. While there was no difference in the basal expression of MIR503HG between SSc and HC cultured dermal fibroblasts, MIR503HG was strongly and consistently induced by TGFβ. Induction of MIR503HG by TGFβ was not limited to skin fibroblasts, but evident also in other cell types relevant for SSc, e.g. pulmonary vascular smooth muscle cells. Time curve analysis revealed that the upregulation of MIR503HG by TGFβ was strongest after 6h reaching 12.8±0.7 induction; and dose curve analysis showed a steady increase of MIR503HG over physiologically relevant TGFβ concentrations. These effects were TGFβR1 dependent as shown by the inhibition experiments with the chemical inhibitors SD208 and SB431542. Moreover, the upregulation of MIR503HG by TGFβ was significantly impaired by silencing of SMAD3, further pointing to an important role of the canonical TGFβ pathway in MIR503HG expression. The knockdown of MIR503HG in skin fibroblasts led to a stron
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2015-eular.2075